After months of uncertainty and controversy, the FDA has given approval to Sarepta's Duchenne muscular dystrophy drug – even though it hasn't yet shown any proof it can slow progress of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback